Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name CC-90010
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CC-90010 CC 90010|CC90010|BET Inhibitor CC-90010 BET Inhibitor (Pan) 27 CC-90010 is a reversible, small molecule drug that binds to BD2 (bromodomain 2) of BET proteins and inhibits interaction with acetylated histones, potentially resulting in disrupted expression of genes that promote cell growth, and inhibition of proliferation of tumor cells overexpressing BET proteins (PMID: 32240793).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown fibrillary astrocytoma not applicable CC-90010 Case Reports/Case Series Actionable In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in a complete response in a patient with IDH-mutant diffuse astrocytoma with MGMT methylation (PMID: 32240793; NCT03220347). 32240793
Unknown unknown non-Hodgkin lymphoma not applicable CC-90010 Phase I Actionable In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in an overall response rate of 2.9% (2/69, 1 complete response, 1 partial response), stable disease in 33.3% (23/69), and a median progression-free survival of 1.9 months in patients with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma (PMID: 32240793; NCT03220347). 32240793
Unknown unknown Advanced Solid Tumor not applicable CC-90010 Phase I Actionable In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in an overall response rate of 2.9% (2/69, 1 complete response, 1 partial response), stable disease in 33.3% (23/69), and a median progression-free survival of 1.9 months in patients with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma (PMID: 32240793; NCT03220347). 32240793
Unknown unknown thymic carcinoma not applicable CC-90010 Case Reports/Case Series Actionable In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in a 17% tumor reduction in a patient with metastatic malignant thymoma (PMID: 32240793; NCT03220347). 32240793
Unknown unknown endometrial carcinoma not applicable CC-90010 Case Reports/Case Series Actionable In a Phase I trial, CC-90010 treatment demonstrated safety, and resulted in a partial response in an endometrial carcinoma patient harboring an ESR1-AKAP12 fusion, ESR1 amplification, and PIK3CA and FGFR2 mutations (PMID: 32240793; NCT03220347). 32240793

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT04047303 Phase I CC-90010 CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma Recruiting


Additional content available in CKB BOOST